Amgen - Rumblings or just end-of-quarter jitters?

Hey everyone, first time posting here. Been with Amgen for a few years now in R&D. Lately, I've been feeling a bit of an uneasy vibe around the office, especially during our recent all-hands. It's not anything concrete, just whispers and a general sense of 'heads down, don't ask too many questions.' No official announcements or anything, but the usual post-holiday energy seems... different. Anyone else picking up on similar trends, or is it just me overthinking things? Wondering if it's a typical end-of-quarter slowdown, or if there's something more substantial going on. Trying not to panic, but the uncertainty is starting to get to me. Any insights from other departments would be appreciated.